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H I G H L I G H T S
• Male Wistar were exposed to repeated ip injection with nicotine for 7 days.
• On the 8th and the 9th day rats were injected icv with antalarmin or astressin2B.
• Horizontal and vertical locomotor activities changed on the 8th and the 9th day.
• Dorsal and ventral striatal dopamine releases changed on the 8th and the 9th day.
• All the changes observed were attenuated by antalarmin, but not astressin2B.







A B S T R A C T
The aim of the present study was to investigate the participation of corticotropin-releasing factor (CRF) receptors
(CRF1 and CRF2) in the alterations of the dorsal and ventral striatal dopamine release and the vertical and
horizontal locomotor activity observed in rats following chronic nicotine treatment and consequent acute
withdrawal. In this purpose, male Wistar rats were exposed to repeated intraperitoneal (ip) injection with ni-
cotine or saline solution for 7 days. On the 8th day or the 9th day the rats were injected intracerebroventricularly
(icv) with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin2B or saline solution. Thirty
minutes after the icv injection the changes of the horizontal and vertical locomotor activity were recorded in an
in vivo conducta system. Immediately after the behavioral recordings the changes of the dorsal and ventral
striatal dopamine release were determined in an in vitro superfusion system. On the 8th day, the horizontal and
vertical locomotor activities and the dorsal and ventral striatal dopamine releases increased significantly in
nicotine-treated rats, compared to the saline-treated ones. On the 9th day, the horizontal locomotor activity and
the dorsal striatal dopamine release increased significantly, whereas the vertical locomotor activity and the
ventral striatal dopamine release decreased significantly in nicotine-treated rats, compared to the saline-treated
ones. All the changes observed were attenuated significantly by antalarmin, but not astressin2B. The present
study demonstrates that the changes of striatal dopamine release and locomotor activity observed following
chronic nicotine treatment and consequent acute withdrawal are mediated by CRF1, but not CRF2, receptor.
1. Introduction
Corticotropin-releasing factor (CRF) is a hypothalamic neuro-
hormone, but also an extrahypothalamic neurotransmitter, that reg-
ulates the neuroendocrine, autonomic and behavioral stress reponses
(Bale et al., 2002; Bale and Vale, 2004; Vale et al., 1981). The actions of
CRF are mediated by two distinct G protein-coupled receptors, CRF
receptor type 1 (CRF1) and CRF receptor type 2 (CRF2) (Chang et al.,
1993; Lovenberg et al., 1995). CRF1 is expressed abundantly in the
central nervous system (CNS), including the cerebral cortex, cerebellum
and striatum (Van Pett et al., 2000). CRF2 is expressed predominantly
in the periphery, and limited centrally to subcortical regions, such as
the hypothalamus, hippocampus and amygdala (Van Pett et al., 2000).
Originally, it was suggested that CRF1 and CRF2 mediate antagonistic
https://doi.org/10.1016/j.brainres.2018.10.028
Received 27 June 2018; Received in revised form 24 October 2018; Accepted 25 October 2018
⁎ Corresponding author at: Department of Pathophysiology, University of Szeged, Semmelweis str. 1, 6725 Szeged, Hungary.
E-mail address: bagosi.zsolt@med.u-szeged.hu (Z. Bagosi).
Brain Research 1706 (2019) 41–47
Available online 26 October 2018
0006-8993/ © 2018 Elsevier B.V. All rights reserved.
T
effects in the CNS, since stimulation of CRF1 provoked activation of the
HPA axis, anxiety and depression, and increase of locomotor activity (at
least in a familial environment), whereas stimulation of CRF2 evoked
anxiolytic and antidepressant effects, and decrease of locomotor ac-
tivity (Bale et al., 2002; Bale and Vale, 2004; Vale et al., 1981). Re-
cently, it was demonstrated that the role of CRF receptors in the stress
responses is not a matter of simple dualism, but it depends upon the
brain regions and neuron populations being activated (Henckens et al.,
2016; Janssen and Kozicz, 2013).
Nicotine is the main psychoactive component of tobacco that causes
addiction. Besides the regulation of the stress responses, CRF has been
implicated in nicotine addiction based on several lines of evidence
(Bruijnzeel and Gold, 2005; Sarnyai et al., 2001). First, acute admin-
istration of nicotine, like any other stressor, evokes a dose-dependent
activation of the hypothalamic–pituitary–adrenal (HPA) axis that is
initiated by hypothalamic CRF (Bruijnzeel and Gold, 2005; Sarnyai
et al., 2001). Second, nicotine withdrawal syndrome resembles the
behavioral stress response that is mediated by extrahypothalamic CRF
(Bruijnzeel and Gold, 2005; Sarnyai et al., 2001). Third, exposure to
stressors is one of the leading causes of nicotine relapse (Bruijnzeel and
Gold, 2005; Sarnyai et al., 2001). Finally, both CRF receptors partici-
pate to the acute, chronic and withdrawal actions of nicotine
(Bruijnzeel et al., 2009; Bruijnzeel, 2012; George et al., 2007; Kamdi
et al., 2009; Marcinkiewcz et al., 2009). The actions of nicotine are
mediated by nicotinic acetylcholine receptors (nAchRs) that are con-
sidered ligand-gated ion channels composed of pentameric combina-
tions of α and β subunits, since normally they respond to acetycholine
and allow natrium or calcium ions to enter the cells (Benowitz, 2010).
Based on their primary sites of expression, nAchRs are classified into
two subtypes: muscle-type nicotinic receptors found in neuromuscular
junctions and neuronal-type nicotinic receptors found on neuronal
bodies and nerve terminals (Benowitz, 2010). The most abundant
neuronal nAchRs are α4β2, α3β4 and α7 located both pre- and post-
synaptically where they can influence the release of other neuro-
transmitters, such as dopamine, glutamate and GABA (Benowitz, 2010).
Some of the psychoactive actions of nicotine are mediated by the
nigrostriatal and mesolimbic pathways (Di Chiara, 2000; Di Chiara
et al., 2004). The nigrostriatal pathway originates in the dopaminergic
neurons located in the substantia nigra and terminates in the putamen
and nucleus caudatus which together constitute the dorsal striatum (Di
Chiara, 2000; Di Chiara et al., 2004). The mesolimbic pathway arises
from the dopaminergic neurons situated in the ventral tegmental area
and projects to the nucleus accumbens that represents the ventral
striatum (Di Chiara, 2000; Di Chiara et al., 2004). Classically, the ni-
grostriatal pathway controls motor behavior, posture and learning of
motor programs and habits, whereas the mesolimbic pathway con-
tributes to motor behavior by mediation of reward, emotion and mo-
tivation (Everitt and Robbins, 2013). Nevertheless, manipulations of
dopamine release in the dorsal and ventral striatum affect motor be-
havior in distinct, but parallel ways, which depend upon the nature of
the cortical and limbic input to these brain structures (Everitt and
Robbins, 2013). Acute administration of nicotine increases the release
of striatal dopamine that is associated with a sensation of reward and
locomotor hyperactivity in rats (Fung and Lau, 1986, 1989). Chronic
administration of nicotine also increases the striatal dopamine release,
although its impact on the locomotor activity depends upon the dose
and schedule of administration (Fung and Lau, 1991, 1992). Usually,
continuous infusion of nicotine several times a day may induce toler-
ance, while repetitive injection once a day may produce sensitization to
the effects of nicotine (Di Chiara, 2000; Di Chiara et al., 2004). Nicotine
also augments glutamate release, which stimulates the release of do-
pamine, and GABA release, which inhibits the release of dopamine.
With long-term exposure to nicotine, some nAchRs become desensi-
tized, but some do not (Benowitz, 2008, 2010). As a result, GABAergic
inhibitory tone diminishes, while glutamatergic excitation continues,
thereby increasing excitation of dopaminergic neurons and enhancing
responsiveness to nicotine (Benowitz, 2008, 2010). Acute withdrawal
following chronic administration of nicotine causes a nicotine with-
drawal syndrome that starts promptly within few hours and peaks
around 24 h following cessation of chronic nicotine administration
(Fung et al., 1996). The nicotine withdrawal syndrome in rats consists
of a somatic component, characterized by locomotor hypoactivity, in-
creased appetite and weight gain and an affective component, re-
presented by anxiety, depression and reward deficit (Kenny and
Markou, 2001). Some of the affective symptoms, such as anxiety and
depression, may persist during chronic nicotine withdrawal (Kenny and
Markou, 2001). The basis of nicotine addiction is a combination of
positive reinforcement, given by the rewarding, positive effects of ni-
cotine, and negative reinforcement, maintained by the avoidance of the
aversive, negative effects of nicotine withdrawal (Benowitz, 2010). The
changes of the dorsal and ventral striatal dopamine release can be
partly or entirely implicated in both forms of reinforcement, and re-
flected in the changes of the horizontal and vertical locomotor activity
(Di Chiara, 2000; Di Chiara et al., 2004). Therefore, these behavioral
and neurochemical parameters can be considered important measures
of nicotine addiction (Fung et al., 1996).
The aim of the present study was to investigate the participation of
CRF1 and CRF2 in the alterations of the dorsal and ventral striatal
dopamine release and the vertical and horizontal locomotor activity
observed in rats following chronic nicotine treatment and consequent
acute withdrawal. In this purpose, male Wistar rats were exposed to
repeated intraperitoneal (ip) injection with 1.4mg/kg nicotine or saline
solution for 7 days, two times/day (at 8:00 and at 20:00). Thus, 12 h
passed between the nicotine treatments. This dose and schedule of
administration should produce plasma nicotine levels in rats similar to
plasma nicotine levels found in an individual who smokes 1–2 packs of
cigarettes a day (Benowitz, 2008). In order to assess the behavioral and
neurochemical changes induced by chronic nicotine treatment and
acute nicotine withdrawal the rats were investigated on the morning of
the 8th day (12 h after the last ip administration) and the 9th day (24 h
after the last ip administration), respectively. Furthermore, the rats
were injected intracerebroventricularly (icv) with selective CRF1 re-
ceptor antagonist antalarmin or selective CRF2 receptor antagonist
astressin2B or saline solution on the 8th day or the 9th day. Thirty
minutes after the icv injection the changes of the horizontal and vertical
locomotor activity were recorded in an in vivo conducta system. Im-
mediately after the behavioral recordings the changes of the dorsal and
ventral striatal dopamine release were determined in an in vitro su-
perfusion system.
2. Results
On the 8th day, the horizontal (Fig. 1) and vertical locomotor ac-
tivity (Fig. 2) and the dorsal (Fig. 3) and ventral striatal dopamine re-
lease (Fig. 4) increased significantly in nicotine-treated rats, compared
with the saline-treated rats. Tukey post-hoc test revealed the following
p values: p < 0.0001 for horizontal locomotor activity, p= 0.0043 for
vertical locomotor activity, p < 0.0001 for dorsal striatal dopamine
release, and p < 0.0001 for ventral striatal dopamine release. All the
changes observed on the 8th day were reduced significantly by icv
treatment with antalarmin, but not astressin2B (Figs. 1–4). Tukey post-
hoc test indicated the following p values: p= 0.0304 for horizontal
locomotor activity, p= 0.0002 for vertical locomotor activity,
p < 0.0001 for dorsal striatal dopamine release, and p < 0.0001 for
ventral striatal dopamine release.
On the 9th day, the horizontal locomotor activity (Fig. 1) and the
dorsal striatal dopamine release (Fig. 3) were increased significantly,
while the vertical locomotor activity (Fig. 2) and the ventral striatal
dopamine release (Fig. 4) were decreased significantly in the nicotine-
treated rats, compared with the saline-treated rats. Tukey post-hoc test
revealed the following p values: p < 0.0001 for horizontal locomotor
activity, p= 0.0033 for vertical locomotor activity, p < 0.0009 for
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dorsal striatal dopamine release, and p < 0.0002 for ventral striatal
dopamine release. All the changes assessed on the 9th day were re-
versed completely by icv treatment with antalarmin, but not astressin2B
(Figs. 1–4). Tukey post-hoc test indicated the following p values:
p < 0.0001 for horizontal locomotor activity, p= 0.0321 for vertical
locomotor activity, p= 0.0022 for dorsal striatal dopamine release, and
p < 0.0001 for ventral striatal dopamine release. A summary of the
effects of the antagonist treatment, the nicotine treatment and the in-
teraction between them is presented in Tables 1–4.
3. Discussion
In rats exposed to 7 days of nicotine treatment (12 h after the last
nicotine administration) we observed increases in horizontal and ver-
tical locomotor activity along with increases in the dorsal and ventral
striatal dopamine release. This finding is in line with previous studies
which reported locomotor hyperactivity on the 4th and the 10th day of
a chronic nicotine exposure (Fung and Lau, 1991, 1992). The authors of
these studies suggested that nicotine-treated rats develop locomotor
hyperactivity in response to nicotine initially due to increases of both
the density of dopamine receptors (D1 and D2) and dopamine con-
centration, and lately due to dopamine receptor supersensitivity in the
striatum (Fung and Lau, 1988). The interpretation of the behavioral
changes observed following chronic nicotine treatment is somewhat
complicated by the observation that the impact of chronic nicotine
exposure on locomotion depend upon sex, age, and housing conditions
(Faraday et al., 1999b, 2001, 2003a,b, 2005). Female animals are less
sensitive to the acute and chronic effects of nicotine, but more sensitive
to the impact of acute nicotine withdrawal, including the neuroendo-
crine and behavioral stress responses, when compared to males
(Bangasser and Wiersielis, 2018; Becker, 2016; Faraday et al., 1999a,
2003b, 2005). As regards the locomotor actions of nicotine in male and
female Long-Evans and Sprague-Dawley rats, the horizontal activity
was more enhanced in Long-Evans females, and the vertical activity was
unaltered in Sprague-Dawley males (Faraday et al., 2003b). Also,
younger animals exhibit increased sensitivity to the positive, rewarding
effects of nicotine and reduced sensitivity to the negative, aversive ef-
fects of nicotine withdrawal which may contribute to the higher risk to
develop nicotine addiction in adolescents, when compared to adults
(Faraday et al., 2003a; Portugal et al., 2012). As regards the locomotor
actions of nicotine, during chronic nicotine administration adolescent
males exhibited a greater locomotor activity, when compared to adult
males or adolescent females (Faraday et al., 2001). During nicotine
cessation, nicotine-treated adolescent males continued to exhibit
greater locomotor activity than saline-treated animals (Faraday et al.,
2001). Another possible factor influencing the results is the housing
condition (Faraday et al., 1999b). In saline-treated rats, group housing
decreased the horizontal and vertical activity and the center time, a
measure of anxiety with effects ocurring sooner in females (Faraday
et al., 1999b). For males, nicotine altered both the horizontal and
vertical activity, increasing these variables for group-housed males, but
decreasing them for individually housed males (Faraday et al., 1999b).
For females, nicotine altered only the center time, reducing this mea-
sure of anxiety for group-housed females (Faraday et al., 1999b).
During nicotine cessation, housing effects appeared more robustly in
males and continued in females (Faraday et al., 1999b). Therefore,
investigation of additional factors, such as sex, age and housing con-
ditions is desirable, but would require more complex experimental
design and statistical analysis.
In rats exposed to 1 day of nicotine withdrawal (24 h after the last
nicotine administration) we expected a decrease of general locomotor
activity and a decrease of global striatal dopamine release, which were
assessed in a previous study following 14 days of nicotine exposure and
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Fig. 1. The horizontal locomotor activity in rats ex-
posed to 7 days of nicotine treatment and 1 day of
withdrawal. Behavioral parameters were determined
on the 8th and the 9th day. Values are presented as
means ± SEM. Statistically significant difference
was accepted for p < 0.05 and indicated with * for
nicotine ip+ saline icv vs. saline ip+ saline icv and
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saline ip + antalarmin icv (6)
saline ip + astressin2B icv (6)
nicotine ip + saline icv (6)
nicotine ip + antalarmin icv (6)





Fig. 2. The vertical locomotor activity in rats ex-
posed to 7 days of nicotine treatment and 1 day of
withdrawal. Behavioral parameters were determined
on the 8th and the 9th day. Values are presented as
means ± SEM. Statistically significant difference
was accepted for p < 0.05 and indicated with * for
nicotine ip+ saline icv vs. saline ip+ saline icv and
with # for nicotine ip+ antalarmin icv vs. nicotine
ip+ saline icv.
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present study only the vertical locomotor activity and the ventral
striatal dopamine release were decreased, while the horizontal loco-
motor activity and the dorsal striatal dopamine release remained in-
creased following acute nicotine withdrawal. The explanation of this
finding might be offered by the authors of this previous study, who
showed a reduction of the maximum number of D2 receptor sites in the
nucleus accumbens, but found no alteration of the density and binding
affinity of dopamine receptors (D1 and D2) in the putamen and nucleus
caudatus (Fung and Lau, 1988). Additionally, the dose and the schedule
of the nicotine exposure may also contribute to the difference between
the previous and present results. Thus, while tolerance is more likely to
be induced by continuous infusion of nicotine (performed in the pre-
vious study), sensitization is frequently induced by intermittent injec-
tion of nicotine (performed in the present study) (Di Chiara, 2000; Di
Chiara et al., 2004). Nonetheless, continuous exposure to nicotine at
doses that result in tolerance to the nicotine-induced sensitization, in-
duces itself a sensitization that is demasked as the tolerance wears off.
Hereby tolerance and sensitization must be regarded as two distinct
adaptive changes that usually require different conditions, but may also
occur following the same dose and schedule of chronic nicotine ex-
posure (Di Chiara, 2000; Di Chiara et al., 2004). Consequently, during
acute nicotine withdrawal these competing phenomena could be man-
ifested differently between the two subdivisions of the striatum and
accordingly, the two aspects of locomotor activity (Di Chiara, 2000; Di
Chiara et al., 2004). The discrepancies between the behavioral and
neurochemical parameters observed following acute nicotine with-
drawal is underlined by the differential nicotinic regulation of the ni-
grostriatal and mesolimbic dopaminergic pathways (Janhunen et al.,
2005; Janhunen and Ahtee, 2007). On one hand, there are clear dif-
ferences in the distribution and characteristics of various nAchR sub-
types between the dorsal and ventral striatum (Exley et al., 2012, 2013;
Janhunen et al., 2005; Janhunen and Ahtee, 2007). Acute nicotine
exposure increases directly the striatal dopamine neurotransmission via
presynaptic nAchRs that are α6β2 and/or α4β2 subunit-containing,
depending on the brain region (Janhunen et al., 2005; Janhunen and
Ahtee, 2007). The nAchR subtypes that regulate dopaminergic neuro-
transmission depend critically upon α5 subunits (non-α6 nAchRs) in
the dorsal striatum and upon α6 subunits (α6 nAchRs) in the ventral
striatum (Exley et al., 2012). Chronic nicotine exposure produces no
change in the control of dopamine release by α6 relative to non-α6
nAchRs in the putamen and nucleus caudatus, but it induces a down-
regulation of the α6 nAchRs and an upregulation of non-α6 nAchRs in
the nucleus accumbens (Exley et al., 2013). In addition, nicotine
modulates the release of dopamine indirectly, through the release of
glutamate and GABA following activation of post-synaptic α7 con-
taining nAchRs (Exley et al., 2012, 2013; Janhunen et al., 2005;
Janhunen and Ahtee, 2007). On the other hand, there are also differ-
ences in the regulation of dopamine release by different nicotinic
agonists (Exley et al., 2012, 2013; Janhunen et al., 2005; Janhunen and
Ahtee, 2007). For example, nicotine stimulates especially the meso-
limbic dopaminergic pathway, in contrast, epibatidine, the most potent
nAchR agonist known to date, stimulates preferentially the nigrostriatal
pathway (Janhunen et al., 2005; Janhunen and Ahtee, 2007). The dif-
fering dose–response curves of the two nicotinic agonists regarding the
dorsal and ventral striatal dopamine release suggest different abilities
for downregulation and desensitization of the nAchRs found in these
brain regions (Janhunen et al., 2005; Janhunen and Ahtee, 2007). This
imbalance in the distribution and the function of nAchRs between the
dorsal and ventral striatum might explain the dopamine dysregulation
assessed during acute nicotine withdrawal.
Taken together, our results demonstrate that the changes of striatal
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Fig. 3. The dorsal striatal dopamine release in rats
exposed to 7 days of nicotine treatment and 1 day of
withdrawal. Biochemical parameters were de-
termined on the 8th and the 9th day. Values are
presented as means ± SEM. Statistically significant
difference was accepted for p < 0.05 and indicated
with * for nicotine ip+ saline icv vs. saline
ip+ saline icv and with # for nicotine ip+ anta-























Ventral striatal dopamine release
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Fig. 4. The ventral striatal dopamine release in rats
exposed to 7 days of nicotine treatment and 1 day of
withdrawal. Biochemical parameters were de-
termined on the 8th and the 9th day. Values are
presented as means ± SEM. Statistically significant
difference was accepted for p < 0.05 and indicated
with * for nicotine ip+ saline icv vs. saline
ip+ saline icv and with # for nicotine ip+ anta-
larmin icv vs. nicotine ip+ saline icv.
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nicotine treatment and consequent acute withdrawal are mediated by
CRF1, but not CRF2. Previous studies have already indicated that
blocking CRF1 would prevent some of the affective symptoms (the
dysphoria and the reward deficit) (Bruijnzeel et al., 2009, 2012; George
et al., 2007; Marcinkiewcz et al., 2009), whereas blocking CRF2 would
reverse some of the somatic symptoms (the excessive food intake and
the increased body weight) of nicotine withdrawal syndrome in rats
(Kamdi et al., 2009). A recent study have also indicated that adminis-
tration of selective CRF2 agonists could ameliorate the anxiety- and
depression-like state developed during acute nicotine withdrawal in
mice (Bagosi et al., 2016). The present study completes the previous
ones, suggesting that both the rewarding, positive reinforcing effects of
nicotine promoted by enhanced striatal dopamine release and the
aversive, negative effects of nicotine withdrawal mediated partly by
deficient striatal dopamine release could be attenuated by administra-
tion of selective CRF1 antagonists. As such, antalarmin may normalize
the striatal dopamine release by blocking CRF1 receptors that regulate
dopamine neuron firing at the level of the substantia nigra and the
ventral tegmental area (Van Pett et al., 2000). Alternatively, antalarmin
may inhibit CRF1 receptors located in the dorsal and ventral striatum,
but also in the amygdala and hippocampus, from where it can modulate
bidirectionally the striatal dopamine release via GABAergic and gluta-
matergic neurotransmission (Bagosi et al., 2006, 2008, 2015; Palotai
et al., 2013a,b). The present study does not exclude the possibility that
the ability of the selective antagonist of CRF1, but not CRF2, to abolish
the behavioral and neurochemical effects of nicotine could simply be
due to the differential distribution of CRF1 and CRF2 receptors in the
substantia nigra and ventral tegmental area or the dorsal and ventral
striatum. Moreover, previous studies demonstrated that CRF1 is ex-
pressed abundantly in all these brain regions, whereas CRF2 is limited
centrally to the hypothalamus, amydgala, and hippocampus (Van Pett
et al., 2000). However, a recent study reported an increased expression
of CRF2 in the dorsal striatum after the development of nicotine-in-
duced sensitization in rats (Carboni et al., 2018). In this order of
thoughts, both CRF1 and CRF2 must be considered potential targets in
the therapy of nicotine addiction.
Table 1
Statistical data for dorsal striatal dopamine release on the 8th and the 9th day.
Source of variation Degrees of freedom Sum of squares Mean square F value p value
Dorsal striatal dopamine release on the 8th day
Antagonist treatment 2.0 16.27 8.133 F(2, 30)=24.28 p < 0.0001
Nicotine treatment 1.0 15.61 15.61 F(1, 30)=46.58 p < 0.0001
Interaction 2.0 2.950 1.475 F(2, 30)=4.40 p=0.0211
Dorsal striatal dopamine release on the 9th day
Antagonist treatment 2.0 5.022 2.511 F(2, 30)=6.58 p=0.043
Nicotine treatment 1.0 14.15 14.15 F(1, 30)=37.12 p < 0.0001
Interaction 2.0 5.336 2.668 F(2, 30)=7.00 p=0.0032
Table 2
Statistical data for ventral striatal dopamine release on the 8th and the 9th day.
Source of variation Degrees of freedom Sum of squares Mean square F value p value
Ventral striatal dopamine release on the 8th day
Antagonist treatment 2.0 24.91 12.46 F(2, 30)=16.77 p < 0.0001
Nicotine treatment 1.0 43.64 43.64 F(1, 30)=58.75 p < 0.0001
Interaction 2.0 26.1 13.00 F(2, 30)=17.51 p < 0.0001
Ventral striatal dopamine release on the 9th day
Antagonist treatment 2.0 20.93 10.46 F(2, 30)=17.13 p < 0.0001
Nicotine treatment 1.0 25.26 25.26 F(1, 30)=41.34 p < 0.0001
Interaction 2.0 9.025 4.513 F(2, 30)=7.39 p=0.0025
Table 3
Statistical data for horizontal locomotor activity on the 8th and the 9th day.
Source of variation Degrees of freedom Sum of squares Mean square F value p value
Horizontal locomotor activity on the 8th day
Antagonist treatment 2.0 351,737 175,869 F(2, 30)= 4.75 p=0.0161
Nicotine treatment 1.0 689,453 689,453 F(1, 30)= 18.62 p=0.0002
Interaction 2.0 292,703 146,351 F(2, 30)= 3.95 p=0.0300
Horizontal locomotor activity on the 9th day
Antagonist treatment 2.0 1.270e 635,248 F(2, 30)= 33.49 p < 0.0001
Nicotine treatment 1.0 2.519e 2.519e F(1, 30)= 132.81 p < 0.0001
Interaction 2.0 1.671e 835,490 F(2, 30)= 44.05 p < 0.0001
Table 4









F value p value
Vertical locomotor activity on the 8th day
Antagonist
treatment
2.0 8433 4217 F(2, 30)= 9.31 p=0.0007
Nicotine
treatment
1.0 6241 6241 F(1, 30)= 13.78 p=0.0008
Interaction 2.0 6762 3381 F(2, 30)= 7.47 p=0.0023
Vertical locomotor activity on the 9th day
Antagonist
treatment
2.0 3627 1814 F(2, 30)= 10.28 p=0.0004
Nicotine
treatment
1.0 3230 3230 F(1, 30)= 18.30 p=0.0002
Interaction 2.0 863.7 431.9 F(2, 30)= 2.45 p=0.1036




Male Wistar rats weighing 150–250 g upon arrival were used
(N=80). Although sexually maturized, the rats were considered ado-
lescents, since they were about 6–7weeks old when the experimental
procedures (treatment, in vivo procedures, etc.) had started (Sengupta,
2013). Pre-adolescence and adolescence are developmental periods
associated with increased vulnerability for nicotine addiction, and ex-
posure to nicotine during these periods may lead to long-lasting
changes in behavioral and neuronal plasticity in different brain regions,
such as the cerebral cortex, hippocampus and striatum (Philpot et al.,
2012; Portugal et al., 2012). In the present study only male animals
were used, as previous studies suggested that the behavior of females
would be influenced by too many variables, including hormonal fluc-
tuations associated with the female reproductive cycle (Bangasser et al.,
2018; Bangasser and Wiersielis, 2018; Becker and Koob, 2016; Dluzen
and Anderson, 1997). However, a recent meta-analysis demonstrated
that female rats were not more variable regarding behavioral, electro-
physiological, neurochemical, and histological measures at any stage of
the estrous cycle than male rats (Becker et al., 2016). Thus, future
studies should include both male and female rats, and power analyses
based on variance in male measures should be sufficient to yield ac-
curate numbers for females as well, even when the estrous cycle is not
taken into consideration. The rats were housed together and kept in
their home cages at a constant temperature on a standard illumination
schedule with 12-h light and 12-h dark periods (lights on from 6:00).
Commercial food and tap water were available ad libitum. To minimize
the effects of nonspecific stress the rats were handled daily. The rats
were treated in accordance with the instructions of the Ethical Com-
mittee for the Protection of Animals in Research, University of Szeged,
Hungary.
4.2. Surgery
The rats were implanted with a stainless steel Luer cannula (10mm
long), aimed at the right lateral cerebral ventricle under anesthesia with
60mg/kg pentobarbital sodium (Euthanasol, CEVA-Phylaxia,
Hungary). The stereotaxic coordinates were 0.2mm posterior and
1.7 mm lateral to the bregma, 3.7mm deep from the dural surface,
according to the stereotaxic atlas of the rat brain (Pellegrino et al.,
1979). Cannulas were secured to the skull with dental cement and ac-
rylate. The rats were allowed for 7 days to recover before experiments
were started. After the experiments were concluded, 10 μl of methylene
blue (Reanal Ltd., Hungary) at 1 g/100ml were injected into the lateral
cerebral ventricle of the decapitated animals and the position of the
cannula was inspected visually. The spread of methylene blue
throughout the ventricular space indicated that the whole amount of
the CRF antagonist got into the ventricles. Animals without the dye in
the lateral cerebral ventricle (8 from 80) were excluded from the final
statistical analysis. No histological preparations were performed.
4.3. Treatments
The rats were treated ip with 1.4mg/kg/10ml nicotine tartrate
(Sigma-Aldrich Inc., USA) or 10ml/kg of 0.9% saline solution (B. Braun
Inc., Germany) for 7 days, two times/day (at 8:00 and at 20:00). One
half of the animals were treated icv with 0.1 µg/2 µl antalarmin (Sigma-
Aldrich Inc., USA), a selective CRF1 antagonist, or 1 µg/2 µl astressin 2B
(Sigma-Aldrich Inc., USA), a selective CRF2 antagonist, or 2 µl of 0.9%
saline solution (B. Braun Inc., Germany) on the 8th day (12 h after the
last ip administration). The other half of the animals were treated icv on
the 9th day (24 h after the last ip administration) based on the same
treatment protocol. Hence, rats were divided in 6 groups: group 1 –
saline ip+ saline icv; group 2 – saline ip+ antalarmin icv; group 3 –
saline ip+ astressin2B icv; group 4 – nicotine ip+ saline icv; group 5 –
nicotine ip+ antalarmin icv; and group 6 – nicotine ip+ astressin2B
icv.
4.4. In vivo procedure
Thirty minutes after the icv injection, the horizontal and vertical
locomotor activities were recorded in an in vivo conducta system (MDE,
Ltd, Germany), which is based on the principles of the open-field test
and was described in our previous studies (Liptak et al., 2013; Szakacs
et al., 2015). The apparatus was a square open-field black box with a
side length of 60 cm, surrounded by a 40 cm high wall. The floor of the
box was divided in 36 (6×6) small squares. Five by five rows of
photocell beams allowed a computer-based system to register the be-
havioral activity of each animal. A 60W light was situated 1m above
the arena floor. Each animal was carried to the experimental room in
their home cage and placed in the center of the box with which they
were familiarized for 5min. Then the horizontal activity, representing a
measure of overall activity and arousal, and the vertical activity, re-
presenting a measure of exploratory and stereotype behavior, were
monitorized for 30min. The box was cleaned between sessions with
96% ethyl-alcohol (Reanal Ltd., Hungary).
4.5. In vitro procedure
After decapitation the changes of dorsal and ventral striatal dopa-
mine releases were determined by an in vitro superfusion system (MDE,
Ltd, Germany) described in our previous studies (Bagosi et al., 2006;
Palotai et al., 2013a). The striatum was isolated and dissected in a Petri
dish filled with ice-cold Krebs solution (Reanal, Hungary). The stereo-
taxic coordinates were 4.0 mm anterior and 1.0mm posterior to the
bregma, according to the stereotaxic atlas of the rat brain (Pellegrino
et al., 1979). The dorsal striatum, including the putamen and the nu-
cleus caudatus, and the ventral striatum, including the nucleus ac-
cumbens, were decapsulated from the surrounding white matter and
separated from each other. Slices of 300 µM were produced with a
McIlwain tissue chopper (Campden Instruments Ltd., UK). The slices
were incubated for 30min in 8ml of Krebs solution, submerged in a
water bath at 37 °C and gassed through a single-use needle with a
mixture of 5% CO2 and 95% O2. During the incubation, the slices were
labelled with 15 µmol of [3H]dopamine (GE Healthcare Life Sciences
Inc., USA) with a specific activity of 14 Ci/mmol. Two tritiated slices
were transferred to each of the four cylindrical perspex chambers of the
superfusion system (MDE, Co. Ltd., Germany). Gold electrodes were
attached to both halves of the superfusion chambers and connected to
an ST-02 electrical stimulator (MDE, Co. Ltd., Germany). A multi-
channel peristaltic Gilson Minipuls 2 pump (Gilson Inc., USA) was used
to maintain a constant superfusion rate of 300 µl/min. The slices were
superfused for 30min to allow tissue equilibrium, and the superfusates
were collected in Eppendorf tubes by a multichannel fraction collector
Gilson FC 203B (Gilson Inc., USA). After 2min electrical stimulation
consisting of square-wave impulses (voltage: 100 V, pulse length: 5 ms,
frequency: 10 Hz) was delivered to each of the four chambers lasting
2min. The sample collecting lasted 32min (2min for each sample) and
the peak of the fractional release was observed at 14min. The remnants
of slices were solubilized in 200ml of Krebs solution, using an ultra-
sonic homogenizer Branson Sonifier 250 (Labequip Ltd., Canada). The
radioactivity in the fractions and the homogenized tissue samples was
measured with a liquid scintillation spectrometer (Tri-carb 2100TR,
Packard Inc., USA) after the addition of 3ml of scintillation fluid (Ul-
tima Gold, Packard Inc., USA). The fractional release was calculated as
a percentage of the radioactivity present in each collected sample
compared to the total radioactivity of the correspondent tissue.
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4.6. Statistical analysis
Statistical analysis of the results was performed by analysis of var-
iance (Prism 7 Statistics, GraphPad Inc., USA). The differences between
groups were determined by two-way ANOVA followed by Tukey’s test
for pairwise comparisons when prerequisites were fulfilled. A prob-
ability level of 0.05 or less was accepted as indicating a statistically
significant difference.
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